Urine Test Study for Bladder Cancer in People With Blood in Urine
Tests a urine assay to detect bladder cancer in adults with microscopic hematuria.
Plain-language title generated from the registry record
Registry title: A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Key facts
- Where
- Dallas, Long Beach, Los Angeles, Newport Beach, and Rochester, United StatesSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with microscopic hematuria (tiny amounts of blood in the urine, seen only under a microscope) to test a new urine test for bladder cancer.
- Age
- 18 years to 90 years
- Sex
- All sexes can join.
- Disease stage
- Microscopic hematuria documented or reported within 3 months before joining.
- Earlier treatment
- No history of bladder cancer or other previous cancer, except basal and squamous cell skin cancer.
Main reasons for not taking part
- History of bladder cancer or other previous cancer (basal and squamous cell skin cancer is allowed)
- Known active urinary tract infection or urinary retention
- Active kidney or bladder stone disease, or kidney insufficiency (creatinine above 2.0 mg/dL (177 µmol/L))
- Ureteral stents, nephrostomy tubes or bowel interposition
- Unable or unwilling to complete the hematuria evaluation (cystoscopy and upper tract imaging)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT03193541, who can take part
Where in United States
- UT Southwestern Medical Center at DallasDallas, United StatesContact: Maricruz IbarraTaking people
- VA Long Beach Healthcare SystemLong Beach, United StatesContact: Mina BehdadTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Amy OppenheimTaking people
- UCLA Medical CenterLos Angeles, United StatesContact: Ankush SachdevaTaking people
- Hoag Memorial Hospital PresbyterianNewport Beach, United StatesContact: Clemente ReyesTaking people
- University of Rochester Medical CenterRochester, United StatesContact: Natalie CarrollTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cedars-Sinai Medical Center
- Trial code
- NCT03193541
- Record updated
- 4 February 2026
- Original description
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.Read full original descriptionShow less
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Inclusion: Age 18 years or older; Have documented or reported microscopic hematuria within 3 month of study enrollment; Willing and able to give written informed consent.
Exclusion: Have recent genitourinary instrumentation (within 10 days prior to signing consent); Have history of BCa; History of previous cancer (excluding basal and squamous cell skin cancer); Have a known active urinary tract infection or urinary retention; Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL); Have ureteral stents, nephrostomy tubes or bowel interposition; Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging).